NCT02398669已完成1 期
An Open-Label, Single Dose Study to Assess Pharmacokinetics, Safety and Tolerability of Lorcaserin Hydrochloride in Obese Pediatric Subjects 6 to 11 Years of Age
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Eisai Inc.
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Plasma PK profile of lorcaserin and its primary metabolites (M1 and M5)
研究概览
简要总结
Study will evaluate the pharmacokinetics (PK), safety and tolerability of a single 10 mg dose of lorcaserin hydrochloride in obese pediatric subjects 6 to 11 years of age.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 6 Years 至 11 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males and females aged 6 years to 11 years (up to 11 years and 364 days), inclusive, at Screening.
- •BMI greater than or equal to 99th percentile for age and gender as defined as:
- •Age Boys Girls 6 21.6 23.0 7 23.6 24.6 8 25.6 26.4 9 27.6 28.2 10 29.3 29.9 11 30.7 31.5
- •but less than or equal to 44kg/m2 at Screening.
- •Provide written informed consent signed by parent/legal guardian prior to entering the study or undergoing any study procedures. A written or verbal assent from the subjects will also be obtained.
- •Females aged at least 8 years should have a negative serum B-human chorionic gonadotropin (beta-hCG) at Visit 1 and a negative urine pregnancy test prior to receiving their first dose of study drug at Visit
- •Willing and able to comply with all aspects of the protocol.
- •Able to swallow a single tablet.
排除标准
- •Clinically significant illness that requires medical treatment within 8 weeks or a clinically significant infection that requires medical attention within 4 weeks of dosing
- •Evidence of disease that may influence the outcome of the study within 4 weeks of dosing (eg, psychiatric disorders and disorders of the gastrointestinal tract, liver, kidney, respiratory system, endocrine system, hematological system, neurological system, cardiovascular system, or subjects who have a congenital abnormality in metabolism)
- •Secondary (chromosomal, endocrine, or metabolic) causes of obesity (eg, Prader-Willi syndrome, Down's Syndrome, untreated hypothyroidism, or Cushing's syndrome).
- •Any history of abdominal surgery that may affect PK evaluations (eg, hepatectomy, nephrotomy, digestive organ resection or any gastrointestinal procedure for the purpose of weight loss, which would slow gastric emptying).
- •Any clinically relevant symptom or organ impairment found by medical history, physical examinations, vital signs, electrocardiogram (ECG) finding, or laboratory test results that require medical treatment at Screening.
- •Special needs subjects who are unable to comprehend trial-related instructions (eg, mild to profound mental retardation, moderate to severe cognitive developmental delay, pervasive developmental disorders, autism).
- •Females who are sexually active.
- •Ongoing epilepsy or other seizure disorder, or use of medications for a seizure disorder within 6 months of the Screening or between Screening and Day
- •History of congestive heart failure, pulmonary arterial hypertension, congenital heart disease, or organ transplantation.
- •Resting heart rate less than 50 or greater than 120 beats/min at Screening or predose on Day
- •Systolic blood pressure (BP) greater than 140 mmHg or less than 90 mmHg or diastolic blood pressure greater than 90 mmHg or less than 60 mmHg at Screening or predose on Day
- •Hypersensitivity to the study drug or any of its excipients.
- •Significant change in diet or level of physical activity within 1 month prior to dosing or change in weight of greater than 5 kg within 3 months prior to dosing.
- •Known to be human immunodeficiency virus (HIV) positive at Screening.
- •Active viral hepatitis (B or C) as demonstrated by positive serology at Screening.
- •Unable to attend scheduled visits (eg, lack of transportation) or lack of a parent/guardian to supervise study participation.
- •Enrolled in another clinical trial that involved pharmacotherapy, or medical device, within 30 days before informed consent.
- •Use of drugs with serotonergic activity within 4 weeks before dosing, including but not limited to selective serotonin-norepinephrine reuptake inhibitors (SNRIs), selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), bupropion, triptans, and drugs that impair metabolism of serotonin (including monoamine oxidase inhibitors [MAOIs], linezolid), dextromethorphan, lithium, tramadol, antipsychotics or other dopamine antagonists.
- •Intake of nutritional supplements, juice, and herbal preparations or other foods or beverages that may affect cytochrome P450 activities or transporters (eg, grapefruit, grapefruit juice, grapefruit containing beverages, apple or orange juice, vegetables from the mustard green family [eg, kale, broccoli, watercress, collard greens, kohlrabi, brussels sprouts, mustard] and charbroiled meats) is prohibited within 2 weeks before dosing.
- •Intake of herbal preparations containing St. John's Wort is prohibited within 4 weeks before dosing.
- •Treatment within 4 weeks of dosing with over-the-counter weight loss products or appetite suppressants (including herbal weight loss agents), or within 3 months of dosing with a prescription weight loss drug (eg, phentermine, sibutramine, orlistat) or lipid dissolving injections (eg, Lipodissolve).
研究组 & 干预措施
lorcaserin 10 mg
Experimental
Cohort 1 - obese pediatric participants between age group of 6 and 8 years (inclusive) Cohort 2 - obese pediatric participants between age group of 9 and 11 years (inclusive)
干预措施: Lorcaserin hydrochloride (Drug)
结局指标
主要结局
Plasma PK profile of lorcaserin and its primary metabolites (M1 and M5)
时间窗: Day 1 at 1, 2, 3, 4, and 6 hours postdose, Day 2 (24 +/- 2 h postdose), Day 3 (48 +/- 2 h postdose), and Day 5 (96 +/- 2 h postdose)
次要结局
- Number of participants with Adverse Events (AEs) / Serious Adverse Events (SAEs) as a measure of safety and tolerabilty(From signing of informed consent until 30 days from participant's last dose or until resolution)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Emicizumab in Healthy Chinese VolunteersHealthy VolunteersHemophilia ANCT03380780Hoffmann-La Roche16
已完成
1 期
Pharmacokinetics of Everolimus in Subjects With Hepatic InsufficiencyHepatic InsufficiencyNCT00968591Novartis Pharmaceuticals34
已完成
1 期
A Study to Assess Zibotentan Pharmacokinetics in Participants With Moderate Hepatic and Moderate Renal ImpairmentHepatic ImpairmentRenal ImpairmentNCT05112419AstraZeneca12
已完成
1 期
Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal FunctionFabry DiseaseNCT01730469Amicus Therapeutics32
已完成
1 期
A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal ImpairmentRenal ImpairmentNCT05489614Amgen33